Correlation analysis of olanzapine plasma concentrations and individual intrinsic factors based on PLS model

Abstract

Abstract: AIM: To evaluate the relationship between olanzapine plasma concentrations and individual intrinsic factors. METHODS: The concentrations of olanzapine in plasma were determined by LC-MS/MS method. The PLS model was used to analysis the correlation between AGE, BMI, WBC, RBC, PLT, HB, Cr, BUN,TP, ALB,AKP, ALT and C_max. RESULTS: Positive correlations between C_max and BMI, WBC, BUN, TP, ALT and negative correlation between C_max and RBC, PLT, HB, Cr, ALB, AKP were observed. Among the total, significant correlations were observed with BMI,WBC,RBC,BUN,TP. Successful fitting result was proved with predictive modeling analysis. CONCLUSION: Individual intrinsic factors should affect C_max of olanzapine,which provided a useful tool for individualized drug therapy.

Key words: Partial least-squares regression (PLS), Olanzapine, Individual intrinsic factors

CLC Number:

R749

YU Ling-yan, LOU Hong-gang, RUAN Zou-rong, JIANG Bo, CHEN Jin-liang. Correlation analysis of olanzapine plasma concentrations and individual intrinsic factors based on PLS model[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1022-1025.

References

[1] Callaghan JT, Bergstrom RF, Ptak LR, et al.Olanzapine - Pharmacokinetic and pharmacodynamic profile[J]. Clin Pharmacokinet, 1999, 37(3): 177-193.
[2] 袁国锋, 俞玉礼. 奥氮平治疗老年精神分裂症患者的疗效观察及对心电图的影响[J]. 中国临床药理学与治疗学, 2011,16(3): 304-307.
[3] 吴小立, 王继辉, 钟智勇,等.阿立哌唑与奥氮平对首发精神分裂症急性期疗效及对催乳素的影响[J].中国临床药理学与治疗学, 2011,16(9): 1016-1020.
[4] Bhana N, Foster RH, Olney R, et al.Olanzapine - An updated review of its use in the management of schizophrenia[J].Drugs, 2001, 61(1): 111-161.
[5] 和喜梅, 刘学武. 临床个体化用药的研究现状和评价[J]. 中国临床药理学与治疗学, 2003, 8(2): 237-240.
[6] FDA: Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER)[EB/OL], 2001. http://www.fda.gov/cder/guidance/index. htm/.
[7] 徐英, 陈崇崇, 杨莉, 等. 基于胆汁酸代谢网络分析中药黄药子的肝毒性[J]. 药学学报, 2011, 46(1): 39-44.
[8] 王毅, 俞凌燕, 范骁辉, 等. 一种基于近红外光谱的天然产物抗氧化活性预测评价方法[J]. 光谱学与光谱分析, 2009,29(9) :2401-2404.
[9] 冯伟峰, 孙升云, 刘康丽,等. 基于PLS模型的血尿酸与代谢综合征各组分的相关性研究[J]. 广东医学, 2010, 31(21): 2772-2775.
[10] Phapale PB, Kim SD, Lee HW, et al.An Integrative Approach for Identifying a Metabolic Phenotype Predictive of Individualized Pharmacokinetics of Tacrolimus[J]. Clin Pharmacol Ther, 2010, 87(4): 426-436.
[11] Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens-When does therapeutic become toxic[J]? J Forensic Sci, 2000,45(2):418-421.

[1]	YAN Pan, SHI Jianfei, LI Jing, WANG Shengdong, WANG Shuqi, WANG Chengpeng, SONG Mingfen. Effects of DRD2 and 5-HTR2A gene polymorphisms and their interaction on olanzapine in the treatment of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1131-1138.
[2]	WAN Ping, LIU Liang, ZHANG Ping, ZHANG Zhongdong. Influential factors of serum concentration/dosage ratio for schizophrenia patients after oral administration of olanzapine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(9): 1024-1029.
[3]	ZHANG Xiaoying, WANG Kang, WU Sha, GUO Peng. Association analysis of low dose olanzapine in controlling mental symptoms of NMDAR encephalitis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1292-1296.
[4]	CUI Lijun, PAN Xin, ZHU Jielin, LI Jianhua. Effect of paliperidone and olanzapine on patients with first-episode schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 466-470.
[5]	NI Ping, LV Hai-long, GUO Xiao-feng, ZHANG Li-li, XU Lin-yong. Comparison of curative effect and clinical influence factors of risperidone and olanzapine in the treatment of acute phrase of schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(2): 182-185.
[6]	ZHANG Yu-qi, XU Wen-wei, CHENG Zao-huo, WU Yue, GU Jun, TANG Li, JI Ping, LI Gui-lin. Efficacy and safety study of the donepezil combined olanzapine flow in the treatment of behavioral and psychological symptoms of dementia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1038-1041.
[7]	ZHONG Zhi-yong, ZHANG Ming, WANG Ji-hui, WU Xiao-li. A retrospective study of risperidone oral solution versus olanzapine tablets in treating brain organic mental disorders [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(9): 1047-1051.
[8]	HANG Rong-hua, CHENG Wan-liang, WANG Rui-quan, WU Ming-fei. Efficacy and executive function of olanzapine and risperidone in the treatment of elderly patients with schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(7): 812-815.
[9]	XU Ben-jian, CHEN Ju-feng. Efficacy and safety of paliperidone extended-release tablets as substituting medication in acute patients with schizophrenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 215-219.
[10]	WU Xiao-li, WANG Ji-hui, ZHONG Zhi-yong, HAN Zi-li. Therapeutic effects of aripiprazole and olanzapine on the patients with first-episode acute schizophrenia and their influence on plasma prolactin level [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 1016-1020.
[11]	WEN Sheng-lin, CHENG Min-feng, WANG Hou-liang. Comparative study of risperidone and olanzapine on plasma non-enzyme antioxidants levels in the schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(9): 1039-1041.
[12]	ZHONG Zhi-yong,WU Xiao-li ,CHEN Min-feng,ZHANG Jin-bei. Control study of Sulpiride and Olanzapine in the treatment of anorexia nervosa [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(4): 423-426.
[13]	YUAN Guo-feng, YU Yu-li. Efficacy and electrocardiogram abnormality of olanzapine in the treatment of old schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 304-308.